**PKR JAIN HEALTHCARE INSTITUTE** NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

A PIONEER DIAGNOSTIC CENTRE

【 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mr. BALJEET SINGH						
AGE/ GENDER : 42 YRS/MALE			PATIENT ID	: 1697133			
COLLECTED BY	:		REG. NO./LAB NO.	<b>: 122412120005</b> : 12/Dec/2024 10:12 AM			
REFERRED BY	:		REGISTRATION DATE				
BARCODE NO.	: 12506115		COLLECTION DATE	: 12/Dec/2024 10:13AM			
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INS	STITUTE	REPORTING DATE	: 12/Dec/2024 11:41AM			
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, A	NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA					
Test Name		Value	Unit	<b>Biological Reference interval</b>			
	CLINI	CAL CHEMIST	FRY/BIOCHEMIST	RY			
		LIPID PRO	FILE : BASIC				
CHOLESTEROL TOTAL: SERUM by CHOLESTEROL OXIDASE PAP		269.86 <sup>H</sup>	mg/dL	OPTIMAL: < 200.0 BORDERLINE HIGH: 200.0 - 239.0 HIGH CHOLESTEROL: > OR = 240.0			
TRIGLYCERIDES: SERUM by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC)		317.35 <sup>H</sup>	mg/dL	OPTIMAL: < 150.0 BORDERLINE HIGH: 150.0 - 199.0 HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0			
HDL CHOLESTEROL (DIRECT): SERUM by SELECTIVE INHIBITION		47.78	mg/dL	LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0 60.0 HIGH HDL: > OR = 60.0			
LDL CHOLESTERO by CALCULATED, SPE		158.61 <sup>H</sup>	mg/dL	OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129 BORDERLINE HIGH: 130.0 - 159.0 HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0			
NON HDL CHOLES' by calculated, spe		222.08 <sup>H</sup>	mg/dL	OPTIMAL: < 130.0 ABOVE OPTIMAL: 130.0 - 159 BORDERLINE HIGH: 160.0 - 189.0 HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0			
VLDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY TOTAL LIPIDS: SERUM by CALCULATED, SPECTROPHOTOMETRY CHOLESTEROL/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY		63.47 <sup>H</sup>	mg/dL	0.00 - 45.00			
		857.07 <sup>H</sup>	mg/dL	350.00 - 700.00			
		5.65 <sup>H</sup>	RATIO	LOW RISK: 3.30 - 4.40 AVERAGE RISK: 4.50 - 7.0			

**DR.VINAY CHOPRA** CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS , MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST

440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. **REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)** 



## PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana) A PIONEER DIAGNOSTIC CENTRE

🔽 0171-2532620, 8222896961 🛛 🖾 pkrjainhealthcare@gmail.com

NAME	: Mr. BALJEET SINGH					
AGE/ GENDER	: 42 YRS/MALE	PATIENT ID	: 1697133			
COLLECTED BY	:	<b>REG. NO./LAB NO.</b>	: 122412120005			
<b>REFERRED BY</b>	:	<b>REGISTRATION DATE</b>	: 12/Dec/2024 10:12 AM			
BARCODE NO.	: 12506115	<b>COLLECTION DATE</b>	: 12/Dec/2024 10:13AM			
CLIENT CODE.	: P.K.R JAIN HEALTHCARE INSTITUTE	<b>REPORTING DATE</b>	: 12/Dec/2024 11:41AM			
CLIENT ADDRESS	: NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA					
Test Name	Value	Unit	Biological Reference interval			

LDL/HDL RATIO: SERUM by Calculated, Spectrophotometry	3.32 <sup>H</sup>	RATIO	MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0 LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0
TRIGLYCERIDES/HDL RATIO: SERUM	6.64 <sup>H</sup>	RATIO	HIGH RISK: > 6.0 3.00 - 5.00

## **INTERPRETATION:**

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for

Total Cholesterol, Triglycerides, HDL & LDL Cholesterol. 2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues. 4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co- primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non HDI

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement

\*\*\* End Of Report \*\*\*





DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)

**NOT VALID FOR MEDICO LEGAL PURPOSE** 

440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. **REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)** 

